« Back to Quality and Patient Safety
- Your First Visit
- Parking Information
- Frequently Asked Questions
- Nurse Navigators
- During Your Treatment
- Coping with Side Effects
- Managing Your Care
- Oncology C.A.R.E. Clinic
- Patient Educational Materials
- Interpreter Services
- Medical Records
-
- Awards & Recognitions
- Hospital Quality and Safety Measures Summary
-
- Acute Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Anal
- Bladder
- Bone & Joint
- Brain/Central Nervous System
- Breast (Female)
- Cervix Uteri
- Chronic Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- Rectum
- Esophagus
- Eye/Orbit
- Hodgkin Lymphoma
- Non Hodgkin Lymphoma
- Kidney/Renal Pelvis
- Larynx
- Liver/Intrahepatic Bile Duct
- Lung & Bronchus
- Melanoma Skin
- Myelodysplastic Syndromes
- Myeloma
- Oral Cavity Pharynx
- Ovary
- Pancreas
- Prostate
- Stomach
- Soft Tissue
- Testis
- Thyroid
- Uterine
- Vagina
- Vulva
- Sylvester Comprehensive Cancer Center's Alex’s Place
- Patient Stories
- We’re Ready to Care for You
- Facial Covering Policy
The five year relative survival rate is an estimate of the proportion of patients who would be expected to survive the effects of their cancer at least five years after their initial cancer diagnosis if the only possible cause of death for the patient was the cancer they were diagnosed with.
The Surveillance, Epidemiology, and End Results (SEER) Program provides information on cancer statistics in an effort to reduce the cancer burden among the U.S. population. SEER is supported by the Surveillance Research Program (SRP) in NCI's Division of Cancer Control and Population Sciences (DCCPS).
All incidence and mortality rates in these reports are age-adjusted to the 2000 US standard population.